RDIF and ChemRar double production of COVID-19 drug

30 November 2020

The Russian Direct Investment Fund, (RDIF), the country’s sovereign wealth fund, and the ChemRar Group, have announced increased production of Avifavir (favipiravir), for treating coronavirus. Due to the launch of full-scale, rolling 24-hour production by ChemRar, output has doubled in November to 200,000 packs per month.

In addition, an audit was completed for the transfer of Avifavir production technology to the sites of Russian partners. On November 25, applications were submitted to the Ministry of Health of Russia for inclusion of two additional contract production sites in the registration certificate to scale up production.

Proven in studies in Russia and elsewhere

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK